Home・Aktien・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Geschlossen

15.15 0.66

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

14.71

Max

15.27

Schlüsselkennzahlen
By Trading Economics
Einkommen	-4.3M -18M
EPS	-0.19
Angestellte	37
EBITDA	-5.3M -17M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+114.53% upside

Dividenden
By Acuity
Nächstes Ergebnis	3. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	32M 1.2B
Vorheriger Eröffnungskurs	14.49
Vorheriger Schlusskurs	15.15

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Aug. 2026, 23:56 UTC

Zions Bancorporation shares are higher in after-market hours, continuing gains amid broader market dynamics influenced by recent U.S. Consumer Price Index data.

12. Aug. 2026, 23:56 UTC

News

Allegro Microsystems shares rose in after-market trading following Benchmark's initiation of coverage with a Buy rating. The stock closed at $42.52.

12. Aug. 2026, 23:56 UTC

JinkoSolar shares are higher in after-market trading, reflecting a modest uptick since Wednesday's close amid U.S. Consumer Price Index data release.

12. Aug. 2026, 23:56 UTC

Yum Brands Inc. shares are higher in after-market trading, reflecting routine performance amid broader market dynamics following the release of U.S. Consumer Price Index data.

12. Aug. 2026, 23:56 UTC

Griffon Corp shares are higher in after-market hours, supported by U.S. Consumer Price Index data easing concerns over Federal Reserve interest rate hikes.

12. Aug. 2026, 23:56 UTC

Social Media

News

STAAR Surgical shares are lower in after-market hours following an EPS miss, despite reporting second-quarter net sales of $93.5 million, a 111% increase.

12. Aug. 2026, 23:56 UTC

MasTec Inc shares are higher in after-market hours, recovering from an earlier dip. The movement aligns with broader market dynamics following U.S. CPI data.

12. Aug. 2026, 23:56 UTC

Molina Healthcare Inc shares are higher in after-market hours, following the release of U.S. Consumer Price Index data that met expectations.

12. Aug. 2026, 23:56 UTC

Ionis Pharmaceuticals Inc. shares are lower in after-market trading, despite remaining above their 20-day moving average and within the upper range for the month.

12. Aug. 2026, 23:56 UTC

ETF Constituents

Vanguard FTSE Emerging Markets ETF shows modest after-market gains, supported by Taiwan Semiconductor and Pinduoduo. The ETF is near its one-month range's upper end.

12. Aug. 2026, 23:56 UTC

Ares Capital Corp shares are lower in after-market hours, continuing a three-session decline amid market volatility following U.S. Consumer Price Index data release.

12. Aug. 2026, 23:56 UTC

DaVita Inc shares are lower in after-market trading following a session peak. The stock remains under pressure, trading below its 20-day moving average.

12. Aug. 2026, 23:56 UTC

ETF Constituents

Correlated Moves

VanEck Gold Miners ETF declines in after-market trading, impacted by top holdings including Pan American Silver's drop and slight decreases in silver prices.

12. Aug. 2026, 23:56 UTC

Chevron Corp shares gained during after-market hours following the release of U.S. Consumer Price Index data, which eased concerns about Federal Reserve interest rate hikes.

12. Aug. 2026, 23:56 UTC

Social Media

Snowflake Inc. shares advanced in after-market trading, buoyed by U.S. CPI data and positive sentiment in tech sector discussions.

12. Aug. 2026, 23:56 UTC

Bristol-Myers Squibb Co shares rose in after-market trading following U.S. Consumer Price Index data, easing concerns about aggressive Federal Reserve interest rate hikes.

12. Aug. 2026, 23:56 UTC

Gogo Inc. shares are higher in after-market trading, following the release of U.S. Consumer Price Index data that met expectations and eased rate hike concerns.

12. Aug. 2026, 23:56 UTC

Comcast shares declined in after-market trading, following the release of U.S. Consumer Price Index data. The stock remains above its 20-day moving average.

12. Aug. 2026, 23:56 UTC

elf Beauty Inc. shares are lower in after-market trading, continuing a four-session decline. The stock remains above its 20-day moving average.

12. Aug. 2026, 23:54 UTC

Ambarella Inc. shares remained roughly flat in after-market hours, with no specific news identified. The stock is positioned above its 20-day moving average.

12. Aug. 2026, 23:52 UTC

UK House Price Balance Shows Slight Improvement at -0.3%, Indicating Ongoing Market Challenges Despite Optimism for Future Stabilization

12. Aug. 2026, 23:52 UTC

RBA Holds Cash Rate at 4.35% Amid Inflation Concerns; Assistant Governor Kent's Upcoming Speech Sparks Market Speculation

12. Aug. 2026, 23:52 UTC

Canada's housing starts data set for release on August 18, following June's decline and amid government initiatives to boost affordable home construction.

12. Aug. 2026, 23:52 UTC

Australia's Consumer Confidence Report Set for August 18 Amidst Cautious Market Sentiment and Economic Volatility.

12. Aug. 2026, 23:52 UTC

Australia's Consumer Confidence Index release on August 18, 2026, faces cautious market expectations amid mixed economic signals and ongoing geopolitical tensions.

12. Aug. 2026, 23:52 UTC

Brazil's Industrial Entrepreneur Confidence Index Expected to Remain Low Amid Economic Uncertainty, Anticipating Continued Pessimism Ahead of August 13 Release.

12. Aug. 2026, 23:52 UTC

Australia's Investment Lending Data Release on August 14 Expected to Impact Housing Market Insights Amid Cautious Sentiment.

12. Aug. 2026, 23:52 UTC

Japan's Upcoming Export Data Release on August 19, 2026, Expected to Reflect Trends in High-Tech Products Amid Global Economic Uncertainties.

12. Aug. 2026, 23:52 UTC

Japan's Upcoming Balance of Trade Data Expected to Show Continued Deficits Amid Rising Imports and Geopolitical Tensions

12. Aug. 2026, 23:52 UTC

JD.Com Inc. shares are lower in after-hours trading, reversing from an early gain amid broader market trends influenced by recent inflation data.

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

114.53% Vorteil

12-Monats-Prognose

Durchschnitt 31.6 USD 114.53%

Hoch 40 USD

Tief 27 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Corvus Pharmaceuticals Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.